Abstract
The verification processes were assessed for 18 important adverse drug reactions. Verification when achieved by formal studies was not obtained through cohort studies such as postmarketing surveillance or other follow up of drug users but through case-control studies or a similar disease orientated approach. When not achieved in this way the most useful aspects of uncontrolled studies were rechallenge and dose-response data. Analysis of the data and of the characteristics of different methods of verification suggested that there were four approaches to earlier discovery. (1) The best system seemed to be some form of record linkage, capable of providing at the same time data on incidence of adverse reactions and on prevalence of drug usage in patients with disease suspected of being drug induced. Until such a system can be established the relative efficacy of alternative approaches appears to be (2) review of all published first alerts, with prompt initiation of case-control or disease orientated studies for verification, (3) postmarketing surveillance of cohorts of drug users, and (4) voluntary reporting systems.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Inman W. H., Vessey M. P., Westerholm B., Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J. 1970 Apr 25;2(5703):203–209. doi: 10.1136/bmj.2.5703.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jick H. The discovery of drug-induced illness. N Engl J Med. 1977 Mar 3;296(9):481–485. doi: 10.1056/NEJM197703032960904. [DOI] [PubMed] [Google Scholar]
- Jick H., Walker A. M., Spriet-Pourra C. Postmarketing follow-up. JAMA. 1979 Nov 23;242(21):2310–2314. [PubMed] [Google Scholar]
- Leibowitz U. Epidemic incidence of Bell's palsy. Brain. 1969 Mar;92(1):109–114. doi: 10.1093/brain/92.1.109. [DOI] [PubMed] [Google Scholar]
- Miller H. Facial paralysis. Br Med J. 1967 Sep 30;3(5569):815–819. doi: 10.1136/bmj.3.5569.815. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Venning G. R. Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide? Br Med J (Clin Res Ed) 1983 Jan 15;286(6360):199–202. doi: 10.1136/bmj.286.6360.199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Venning G. R. Identification of adverse reactions to new drugs. II (continued): How were 18 important adverse reactions discovered and with what delays? Br Med J (Clin Res Ed) 1983 Jan 29;286(6362):365–368. doi: 10.1136/bmj.286.6362.365. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Venning G. R. Identification of adverse reactions to new drugs. II--How were 18 important adverse reactions discovered and with what delays? Br Med J (Clin Res Ed) 1983 Jan 22;286(6361):289–292. doi: 10.1136/bmj.286.6361.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Venning G. R. Identification of adverse reactions to new drugs. III: Alerting processes and early warning systems. Br Med J (Clin Res Ed) 1983 Feb 5;286(6363):458–460. doi: 10.1136/bmj.286.6363.458. [DOI] [PMC free article] [PubMed] [Google Scholar]